SOPHiA GENETICS is a Swiss health tech company on a mission to democratize data-driven medicine globally through its AI-powered, cloud-native SOPHiA DDM™ platform. The company has achieved significant scale, having analyzed over 2.3 million genomic profiles and serving more than 990 healthcare institutions across 75+ countries. Its strategy centers on expanding its platform's capabilities from genomics into radiomics and multimodal data analysis, while deepening its network effects within the clinical and biopharma ecosystems to drive adoption and insights.
OncologyRare and Inherited Disorders
Technology Platform
SOPHiA DDM™ is a cloud-native, AI-powered SaaS platform that analyzes complex genomic, radiomic, and multimodal health data to deliver actionable insights for clinical decision support in oncology and rare diseases.
Funding History
4
Total raised:$346M
IPO$234MUndisclosed
Series C$77MGeneration Investment Management
Series B$30MBalderton Capital
Series A$5MBalderton Capital
Opportunities
Expansion into radiomics and multimodal data analysis represents a significant TAM expansion beyond genomics.
The growing BioPharma segment offers a high-value revenue stream for clinical trial optimization and companion diagnostic development.
The global 'democratization' thesis opens underserved geographic markets.
Risk Factors
Intense competition from large diagnostic incumbents and agile software startups.
The path to sustained profitability requires careful management of growth investments.
Evolving regulatory and reimbursement landscapes for AI-driven clinical software pose ongoing challenges.
Competitive Landscape
Competes with integrated NGS vendors (Illumina, Thermo Fisher), pure-play genomic software firms (Fabric Genomics, DNAnexus), and in-house lab solutions. Key differentiators are platform agnosticism, a global network effect, and a broadening focus into radiomics and multimodal data integration.
